Salta al contenuto principale
Passa alla visualizzazione normale.

LIGIA JULIANA DOMINGUEZ RODRIGUEZ

Sarcopenia reduces quality of life in the long-term: longitudinal analyses from the English longitudinal study of ageing

  • Autori: Veronese, N.; Koyanagi, A.; Cereda, E.; Maggi, S.; Barbagallo, M.; Dominguez, L.J.; Smith, L.
  • Anno di pubblicazione: 2022
  • Tipologia: Articolo in rivista
  • OA Link: http://hdl.handle.net/10447/568067

Abstract

Purpose: Mixed findings exist for sarcopenia/quality of life (QoL) relationship. Moreover, the majority of studies in this area have utilized a cross-sectional design or specific clinical populations. Therefore, the aim of the present study was to examine the association between sarcopenia at baseline and QoL at 10 years follow-up in a large representative sample of older English adults. Methods: Sarcopenia was diagnosed as having low handgrip strength and low skeletal muscle mass index. QoL was measured using the CASP (control, autonomy, self-realisation and pleasure)-19, with higher values reflecting higher QoL. Multivariable logistic regression analysis was conducted to assess prospective associations between sarcopenia at baseline and poor QoL at follow-up; generalized linear model with repeated measures was used for reporting mean changes during follow-up between sarcopenia and not. Results: Among 4044 older participants initially included at baseline (mean age: 70.7 years; 55.1% females), 376 had sarcopenia. In the multivariable analysis, after adjusting for several potential confounders, sarcopenia at baseline was associated with a higher incidence of poor QoL (odds ratio, OR = 5.82; 95% confidence interval, CI 3.45–9.82). After matching for QoL values at baseline and adjusting for potential confounders, people with sarcopenia reported significantly lower values in CASP-19 (mean difference = − 3.94; 95% CI − 4.77 to − 3.10). Conclusions: In this large representative sample of older English adults, it was observed that sarcopenia at baseline was associated with worse scores of QoL at follow-up compared to those without sarcopenia at baseline. It may be prudent to target those with sarcopenia to improve QoL.